Q1 2025 Fresenius SE & Co KGaA Earnings Call Transcript
Key Points
- Fresenius SE & Co KGaA (FSNUF) reported a strong start to 2025 with double-digit EPS growth, reflecting effective capital management and portfolio optimization.
- The company achieved a 12% increase in core EPS in Q1, driven by growth and earnings expansion across its businesses.
- Kabi's EBIT margin increased to 16.8%, supported by strong performance in biopharma, nutrition, and medtech sectors.
- Helios delivered strong top-line growth, with Spain achieving a 13.1% EBIT margin and 23% EBIT growth at constant currency.
- The company successfully reduced its stake in Fresenius Medical Care, using proceeds to enhance returns and lower debt, strengthening its balance sheet.
- The absence of energy relief in Germany affected Helios' EBIT margin, which was down year-on-year.
- Potential impacts from global trade uncertainties and tariff policies could affect future economic activity.
- The weakening of the US dollar against the euro could negatively impact reported revenue and EBIT if it persists.
- The company faces challenges in maintaining momentum amidst a dynamic macroeconomic and geopolitical environment.
- Kabi's Q2 performance may be impacted by the absence of the high-margin product Keto in China, affecting revenue and EBIT.
Hello everyone. Good afternoon and good morning wherever you may be. Welcome to our Q1 2025 earnings call and webcast.
Presentation It was emailed to our distribution list earlier today and is available on Freenius.com. On slide 2 of the presentation, you'll find the usual safe harbor statement unless stated otherwise, we'll comment on our performance using constant exchange rates, or CR.
Today, as usual, I'm joined by Michael and Sarah, who will take you through the details of another strong performance. We estimate that the call will last approximately 1 hour with the presentation taking around 35 to 40 minutes, with the remaining time for your questions. Obviously, to give everyone the chance to participate, please limit your questions to 1 to 2 in the first instance, and we can always come back for an additional round if needed.
And with that, I'm delighted to hand the call over to Michael.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
